{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T21:23:34Z","timestamp":1768080214973,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,7,21]],"date-time":"2018-07-21T00:00:00Z","timestamp":1532131200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009287","name":"NSW Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009287","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009287","name":"NSW Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009287","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Translational Cancer Research Network"},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["RG171797"],"award-info":[{"award-number":["RG171797"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001171","name":"Cancer Institute NSW","doi-asserted-by":"publisher","award":["15\/TRC\/1-03"],"award-info":[{"award-number":["15\/TRC\/1-03"]}],"id":[{"id":"10.13039\/501100001171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"NHMRC","doi-asserted-by":"publisher","award":["APP1092856"],"award-info":[{"award-number":["APP1092856"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ygyno.2018.07.013","type":"journal-article","created":{"date-parts":[[2018,7,25]],"date-time":"2018-07-25T01:48:36Z","timestamp":1532483316000},"page":"527-533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials"],"prefix":"10.1016","volume":"150","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9134-2118","authenticated-orcid":false,"given":"Nicola S.","family":"Meagher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Voss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Budden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi Nam Ignatius","family":"Pang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0057-4744","authenticated-orcid":false,"given":"Anna","family":"deFazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan J.","family":"Ramus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael L.","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.07.013_bb0005","doi-asserted-by":"crossref","DOI":"10.1097\/01.pgp.0000101080.35393.16","article-title":"The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin","volume":"23","author":"Seidman","year":"2004","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2018.07.013_bb0010","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/cncr.25460","article-title":"Advanced stage mucinous adenocarcinoma of the ovary is both rare and highly lethal: a gynecologic oncology group study","volume":"117","author":"Zaino","year":"2011","journal-title":"Cancer"},{"issue":"9 Suppl 3","key":"10.1016\/j.ygyno.2018.07.013_bb0015","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/IGC.0000000000000296","article-title":"Gynecologic Cancer InterGroup (GCIG) consensus review for mucinous ovarian carcinoma","volume":"24","author":"Ledermann","year":"2014","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2018.07.013_bb0020","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/s12885-015-1421-8","article-title":"Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms","volume":"15","author":"Mackenzie","year":"2015","journal-title":"BMC Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2018.07.013_bb0025","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S1470-2045(11)70058-4","article-title":"Mucinous carcinomas of the ovary and colorectum: different organ, same dilemma","volume":"12","author":"Kelemen","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.07.013_bb0030","doi-asserted-by":"crossref","DOI":"10.1097\/00000478-200307000-00014","article-title":"Primary and metastatic mucinous adenocarcinomas in the ovaries: incidence in routine practice with a new approach to improve intraoperative diagnosis","volume":"27","author":"Seidman","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2018.07.013_bb0035","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/00000478-200303000-00001","article-title":"The distinction between primary and metastatic mucinous carcinomas of the ovary: gross and histologic findings in 50 cases","volume":"27","author":"Lee","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2018.07.013_bb0040","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ygyno.2010.02.010","article-title":"Unmasking the complexities of mucinous ovarian carcinoma","volume":"117","author":"Frumovitz","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2018.07.013_bb0045","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1200\/JCO.2004.08.078","article-title":"Mucinous epithelial ovarian cancer: a separate entity requiring specific treatment","volume":"22","author":"Hess","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.013_bb0050","doi-asserted-by":"crossref","DOI":"10.1111\/IGC.0b013e3181dd0110","article-title":"Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer","volume":"20","author":"Mackay","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"7","key":"10.1016\/j.ygyno.2018.07.013_bb0055","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1097\/IGC.0000000000000473","article-title":"Survival of patients with mucinous ovarian carcinoma and ovarian metastases: a population-based cancer registry study","volume":"25","author":"Simons","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2018.07.013_bb0060","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2006.10.2517","article-title":"Prognostic factors for stage III epithelial ovarian cancer: a gynecologic oncology group study","volume":"25","author":"Winter","year":"2007","journal-title":"J. Clin. Oncol."},{"issue":"15 suppl","key":"10.1016\/j.ygyno.2018.07.013_bb0065","doi-asserted-by":"crossref","first-page":"5528","DOI":"10.1200\/jco.2015.33.15_suppl.5528","article-title":"Multicentre trial of carboplatin\/paclitaxel versus oxaliplatin\/capecitabine, each with\/without bevacizumab, as first line chemotherapy for patients with mucinous epithelial ovarian cancer (mEOC)","volume":"33","author":"Gore","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.013_bb0070","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.critrevonc.2016.03.015","article-title":"Mucinous ovarian cancer: a therapeutic review","volume":"102","author":"Xu","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ygyno.2018.07.013_bb0075","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-9-433","article-title":"HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy","volume":"9","author":"McAlpine","year":"2009","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2018.07.013_bb0080","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s13073-015-0210-y","article-title":"Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors","volume":"7","author":"Ryland","year":"2015","journal-title":"Genome Med."},{"issue":"1","key":"10.1016\/j.ygyno.2018.07.013_bb0085","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/path.4088","article-title":"Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas","volume":"229","author":"Anglesio","year":"2013","journal-title":"J. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2018.07.013_bb0090","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061565","article-title":"HER2 amplification and clinicopathological characteristics in a large Asian cohort of rare mucinous ovarian cancer","volume":"8","author":"Chay","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2018.07.013_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/S0090-8258(03)00264-6","article-title":"Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma","volume":"90","author":"Gemignani","year":"2003","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.07.013_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexmp.2013.08.004","article-title":"TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type","volume":"95","author":"Rechsteiner","year":"2013","journal-title":"Exp. Mol. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2018.07.013_bb0105","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0090-8258(03)00264-6","article-title":"Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma","volume":"90","author":"Gemignani","year":"2003","journal-title":"Gynecol. Oncol."},{"issue":"8","key":"10.1016\/j.ygyno.2018.07.013_bb0110","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","volume":"7","year":"2017","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.ygyno.2018.07.013_bb0115","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1198\/000313007X172556","article-title":"Much ado about nothing: a comparison of missing data methods and software to fit incomplete data regression models","volume":"61","author":"Horton","year":"2007","journal-title":"Am. Stat."},{"key":"10.1016\/j.ygyno.2018.07.013_bb0120","series-title":"Classification and Regression by RandomForest","author":"Liaw","year":"2001"},{"issue":"19","key":"10.1016\/j.ygyno.2018.07.013_bb0125","doi-asserted-by":"crossref","first-page":"3012","DOI":"10.1093\/bioinformatics\/btw325","article-title":"GenVisR: genomic visualizations in R","volume":"32","author":"Skidmore","year":"2016","journal-title":"Bioinformatics (Oxford, England)"},{"key":"10.1016\/j.ygyno.2018.07.013_bb0130","series-title":"Cluster Analysis","author":"Everitt","year":"2011"},{"issue":"15 suppl","key":"10.1016\/j.ygyno.2018.07.013_bb0135","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1200\/jco.2015.33.15_suppl.5540","article-title":"Molecular profiling of mucinous epithelial ovarian carcinomas (mEOC): Opportunities for clinical trials","volume":"33","author":"Friedlander","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2018.07.013_bb0140","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/IGC.0b013e3181dd0110","article-title":"Prognostic relevance of uncommon ovarian histology in women with stage III\/IV epithelial ovarian cancer","volume":"20","author":"Mackay","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"19","key":"10.1016\/j.ygyno.2018.07.013_bb0145","doi-asserted-by":"crossref","first-page":"5267","DOI":"10.1158\/1078-0432.CCR-12-1103","article-title":"Pre-invasive ovarian mucinous tumors are characterized by <em>CDKN2A<\/em> and <em>RAS<\/em> pathway aberrations","volume":"18","author":"Hunter","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2018.07.013_bb0150","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2006.06.1101","article-title":"RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non\u2013small-cell lung cancer","volume":"24","author":"Bepler","year":"2006","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2018.07.013_bb0155","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1056\/NEJMoa060570","article-title":"DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy","volume":"35","author":"Olaussen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.07.013_bb0160","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrc1074","article-title":"5-fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2018.07.013_bb0165","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.76.5966","article-title":"Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/neu","author":"Fader","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2018.07.013_bb0170","article-title":"The prognostic role of the class III \u03b2-tubulin in non-small cell lung cancer (NSCLC) patients receiving the taxane\/vinorebine-based chemotherapy: a meta-analysis","volume":"9","author":"Yang","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.ygyno.2018.07.013_bb0175","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1002\/ijc.21701","article-title":"BRAF mutation, CpG island methylator phenotype and microsatellite instability occur more frequently and concordantly in mucinous than non-mucinous colorectal cancer","volume":"118","author":"Tanaka","year":"2006","journal-title":"Int. J. Cancer"},{"issue":"26","key":"10.1016\/j.ygyno.2018.07.013_bb0180","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ygyno.2018.07.013_bb0185","series-title":"Recent Insights into Mucinous Ovarian Carcinoma","author":"Ricci","year":"2018"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818310771?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818310771?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,21]],"date-time":"2019-10-21T03:19:39Z","timestamp":1571627979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818310771"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0090825818310771"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.07.013","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does the primary site really matter? Profiling mucinous ovarian cancers of uncertain primary origin (MO-CUP) to personalise treatment and inform the design of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.07.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}